Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherSPECIAL CONTRIBUTIONS

MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry—Standardization of Nomenclature

Wesley E. Bolch, Keith F. Eckerman, George Sgouros and Stephen R. Thomas
Journal of Nuclear Medicine March 2009, 50 (3) 477-484; DOI: https://doi.org/10.2967/jnumed.108.056036
Wesley E. Bolch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keith F. Eckerman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George Sgouros
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen R. Thomas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

    • View popup
    TABLE 1

    Quantities, Parameters, Symbols, and Units Used in the MIRD and ICRP Dosimetry Schema (Listed in Order of Appearance in Equations 1–17)

    Embedded Image
    • View popup
    TABLE 2

    Recommended Tissue-Weighting Factors

    TissueEmbedded ImageEmbedded Image
    Active bone marrow, colon, lung, stomach, breast, remainder tissues*0.120.72
    Gonads0.080.08
    Bladder, esophagus, liver, thyroid0.040.16
    Endosteal tissues, brain, salivary glands, skin0.010.04
    Total1.00
    • ↵* Remainder tissues are adrenal glands, extrathoracic airways, gallbladder, heart, kidneys, lymphatic nodes, skeletal muscle, oral mucosa, pancreas, prostate (♂), small intestine, spleen, thymus, and uterus/cervix (♀). Data are taken from ICRP publication 103 (8).

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 50 (3)
Journal of Nuclear Medicine
Vol. 50, Issue 3
March 2009
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry—Standardization of Nomenclature
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry—Standardization of Nomenclature
Wesley E. Bolch, Keith F. Eckerman, George Sgouros, Stephen R. Thomas
Journal of Nuclear Medicine Mar 2009, 50 (3) 477-484; DOI: 10.2967/jnumed.108.056036

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry—Standardization of Nomenclature
Wesley E. Bolch, Keith F. Eckerman, George Sgouros, Stephen R. Thomas
Journal of Nuclear Medicine Mar 2009, 50 (3) 477-484; DOI: 10.2967/jnumed.108.056036
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • PHYSICAL QUANTITIES
    • QUANTITIES RELEVANT TO THE RISK OF STOCHASTIC EFFECTS
    • QUANTITIES RELEVANT TO THE RISK OF DETERMINISTIC EFFECTS
    • CONCLUSION
    • APPENDIX
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Preclinical Evaluation of 213Bi- and 225Ac-Labeled Low-Molecular-Weight Compounds for Radiopharmaceutical Therapy of Prostate Cancer
  • PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates
  • 11C-PABA as a PET Radiotracer for Functional Renal Imaging: Preclinical and First-in-Human Study
  • OpenDose: Open-Access Resource for Nuclear Medicine Dosimetry
  • PSA-targeted Alpha-, Beta- and Positron Emitting Immuno-Theranostics in Murine Prostate Cancer Models and Non-Human Primates
  • Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients
  • Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors
  • Human Radiation Dosimetry for Orally and Intravenously Administered 18F-FDG
  • Preclinical Evaluation of 203/212Pb-Labeled Low-Molecular-Weight Compounds for Targeted Radiopharmaceutical Therapy of Prostate Cancer
  • PARaDIM: A PHITS-Based Monte Carlo Tool for Internal Dosimetry with Tetrahedral Mesh Computational Phantoms
  • Melanocortin 1 Receptor-Targeted {alpha}-Particle Therapy for Metastatic Uveal Melanoma
  • Biodistribution and Radiation Dosimetry of 124I-DPA-713, a PET Radiotracer for Macrophage-Associated Inflammation
  • The Relevance of Dosimetry in Precision Medicine
  • Patient-Specific Computational Model and Dosimetry Calculations for PET/CT of a Patient Pregnant with Twins
  • Comparative Dosimetry for 68Ga-DOTATATE: Impact of Using Updated ICRP Phantoms, S Values, and Tissue-Weighting Factors
  • Whole-Body Voxel-Based Personalized Dosimetry: The Multiple Voxel S-Value Approach for Heterogeneous Media with Nonuniform Activity Distributions
  • 2018 ACC/HRS/NASCI/SCAI/SCCT Expert Consensus Document on Optimal Use of Ionizing Radiation in Cardiovascular Imaging: Best Practices for Safety and Effectiveness: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways
  • Dose Mapping After Endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days
  • RADAR Dose Estimate Report: A Compendium of Radiopharmaceutical Dose Estimates Based on OLINDA/EXM Version 2.0
  • Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive?
  • Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT-Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer
  • Microarray Studies on 211At Administration in BALB/c Nude Mice Indicate Systemic Effects on Transcriptional Regulation in Nonthyroid Tissues
  • 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology
  • Whole-Body Distribution and Radiation Dosimetry of 11C-Elacridar and 11C-Tariquidar in Humans
  • Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer
  • Radiosensitivity of Prostate Cancer Cell Lines for Irradiation from Beta Particle-emitting Radionuclide 177Lu Compared to Alpha Particles and Gamma Rays
  • Uncertainty Quantification in Internal Dose Calculations for Seven Selected Radiopharmaceuticals
  • Preclinical Evaluation of 86Y-Labeled Inhibitors of Prostate-Specific Membrane Antigen for Dosimetry Estimates
  • Intratherapeutic Biokinetic Measurements, Dosimetry Parameter Estimates, and Monitoring of Treatment Efficacy Using Cerenkov Luminescence Imaging in Preclinical Radionuclide Therapy
  • Dose Escalation and Dosimetry of First-in-Human {alpha} Radioimmunotherapy with 212Pb-TCMC-Trastuzumab
  • Fetal and Maternal Absorbed Dose Estimates for Positron-Emitting Molecular Imaging Probes
  • MIRD Pamphlet No. 25: MIRDcell V2.0 Software Tool for Dosimetric Analysis of Biologic Response of Multicellular Populations
  • A Compartmental Model of Mouse Thrombopoiesis and Erythropoiesis to Predict Bone Marrow Toxicity After Internal Irradiation
  • Comparative Analysis of Transcriptional Gene Regulation Indicates Similar Physiologic Response in Mouse Tissues at Low Absorbed Doses from Intravenously Administered 211At
  • MIRD Pamphlet No. 23: Quantitative SPECT for Patient-Specific 3-Dimensional Dosimetry in Internal Radionuclide Therapy
  • A Compartmental Model for Biokinetics and Dosimetry of 18F-Choline in Prostate Cancer Patients
  • Developing an Action Plan for Patient Radiation Safety in Adult Cardiovascular Medicine: Proceedings From the Duke University Clinical Research Institute/American College of Cardiology Foundation/American Heart Association Think Tank Held on February 28, 2011
  • Developing an Action Plan for Patient Radiation Safety in Adult Cardiovascular Medicine: Proceedings From the Duke University Clinical Research Institute/American College of Cardiology Foundation/American Heart Association Think Tank Held on February 28, 2011
  • Minimizing and Communicating Radiation Risk in Pediatric Nuclear Medicine
  • An Approach for Balancing Diagnostic Image Quality with Cancer Risk: Application to Pediatric Diagnostic Imaging of 99mTc-Dimercaptosuccinic Acid
  • Patient-Specific Radiation Dosimetry of 99mTc-HYNIC-Tyr3-Octreotide in Neuroendocrine Tumors
  • MRI Measurement of Bone Marrow Cellularity for Radiation Dosimetry
  • Minimizing and Communicating Radiation Risk in Pediatric Nuclear Medicine
  • Radiation Dosimetry of 82Rb in Humans Under Pharmacologic Stress
  • Human Biodistribution and Radiation Dosimetry of 82Rb
  • Dosimetry and thyroid cancer: the individual dosage of radioiodine
  • MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of {alpha}-Particle Emitters for Targeted Radionuclide Therapy
  • Intraperitoneal {alpha}-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab')2--A Phase I Study
  • Google Scholar

More in this TOC Section

  • The Use of Published Clinical Study Reports to Support U.S. Food and Drug Administration Approval of Imaging Agents
  • Variations in PET/MRI Operations: Results from an International Survey Among 39 Active Sites
  • American Society of Nuclear Cardiology and Society of Nuclear Medicine and Molecular Imaging Joint Position Statement on the Clinical Indications for Myocardial Perfusion PET
Show more Special Contributions

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire